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Conclusion: Despite the numerous publications on focal 
therapy in prostate cancer, primary FRT is largely 
unexplored. Radiotherapy appears to be particularly suitable 
as a focal approach, since it has an established biological 
basis, known tumoricidal activity, possibility of dose 
differentiation, large availability of high-precision dose 
delivery techniques, limited or no invasiveness and 
familiarity to radiation oncologists and urologists. However, 
when applied as primary FRT, its use remains investigational 
since numerous questions remain unmet: consensus on the 
initial diagnostic tools, the optimization of technical 
parameters for therapy delivery, follow-up exams and 
scheduling, tumour control and toxicity profile, response 
evaluation and failure definition, salvage therapy and cost-
benefit.  
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Purpose or Objective: Changes in prostate and tumour ADC 
values during radiotherapy (RT) may aid prediction of 
response to treatment. Intermediate and high risk patients 
are likely to receive neoadjuvant hormone therapy (NA-HT) 
prior to RT, causing reduction in prostate and tumour volume 
and changes in ADC values. It is unclear how this affects 
further ADC changes during subsequent treatment. We 
assessed ADC values in prostate tumour and normal tissue 
during RT after NA-HT. 
 
Material and Methods: Fifteen patients with ≥T2b disease 
who were due to receive RT (60 Gy in 20 fractions) were 
recruited after 3 months of NA-HT. Patients underwent three 
1.5 T MRI examinations: post NA-HT (one week prior to RT), 
at the end of the third week of treatment, and eight weeks 
after RT completion. The imaging protocol included T2 
weighted and diffusion weighted imaging, acquired using the 
cardiac coil (EPI with TR/TE 8000/70 ms, b = 100, 400, 800 
s/mm²). ADC maps were processed offline (ADCmap for 
Osirix). Normal central gland (CG), peripheral zone (PZ) and 
tumour were outlined on T2w images by a radiologist expert 
in prostate MRI, with pre-NA-HT imaging (T2w and DWI) 
available in 12 patients to aid identification. If disease was 
not clearly visible, clinical findings and biopsy results were 
used to aid delineation. CG, PZ and tumour regions were 
transferred to the ADC maps and median values extracted 
along with interquartile ranges. A Mann-Whitney U test was 
used to analyse differences between tumour and normal 
tissue regions at the three time points. 
 
Results: 13 patients completed all scans, 2 patients missed 1 
and 2 scans respectively. After NA-HT, there was a significant 
difference between median tumour and PZ (p=0.009) and 
tumour and CG (p=0.002) (median values plotted in figure 1). 
At the other time points, there was no difference between 
tumour and normal tissue ADCs. 
 
 
 
Conclusion: The ADC values display a similar pattern to that 
seen in previous studies for patients receiving RT alone. The 
difference between tumour and normal tissue was smaller at 
baseline than has been seen in other work without NA-HT. 
This may be due to a reduction in normal tissue ADC during 
induction therapy, whilst tumour ADC values could have 
increased due to tumour shrinkage. Variation in imaging 
protocol for ADC measurement compared to previous studies 
may also play a role. The reduced magnitude of changes in 
tumour ADC seen during RT after NA-HT may make its use as 
a predictive tool for treatment response more challenging in 
this group of patients. 
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Purpose or Objective: At the time of a biochemical 
recurrence after prostatectomy it is important to distinguish 
patients who have a local recurrence from patients with 
distant metastasis. PET/CT and MRI are important imaging 
modalities that can be used in this scenario. The purpose of 
this study was to investigate the outcomes and toxicities of 
patients in a large single-institution cohort treated with 
salvage radiotherapy (sRT) and dose escalation up to 72 Gy. 
Boost planning was based on MRI or PET/CT. 
 
Material and Methods: From 2008 to 2012 290 patients who 
received sRT were included into the analysis. Patients with a 
PSA > 1 ng/ml or a PSA doubling time > 3 months received a 
Choline PET/CT before the start of radiotherapy. 
Additionally, in most patients MRI of the pelvis was 
conducted. If there was a macroscopic tumor recurrence, 
defined as local recurrence in the prostate bed in MRI or PET 
tracer uptake, radiation therapy to the prostatic bed was 
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complemented by a boost to local recurrence to a total dose 
of 72 Gy. In case of no macroscopic tumor recurrence the 
total dose was 66.6 Gy. 
 
Results: MRI was performed in 233 patients and PET/CT was 
performed in 169 patients. A local recurrence in the prostate 
bed could be detected in 123 patients with a median volume 
of 0.5 ml (range, 0.03 – 125.00 ml). The median follow-up 
time after RT was 49.4 months (range, 7.3 – 86.1 months). A 
total of 85 patients experienced a biochemical failure with a 
median time of 19.8 months (range, 1.9 – 76.1 months) after 
sRT. Median PSA level at the time of recurrence was 0.91 
ng/ml (range, 0.01 – 2224.00 ng/ml). The median BRFS after 
radiation therapy was 73 months. The estimated 3- and 5-
year bRFS was 72% and 55%, respectively. On multivariate 
analysis, Gleason Score (hazard ratio, 6.946; p = 0.006) and 
pre-RT PSA level (hazard ratio, 2.265; p = 0.022) were 
statistically significant predictors for bRFS. bRFS was similar 
in patients with a macroscopic recurrence in either MRI or 
PET/CT compared to patients without a macroscopic 
recurrence. 5-year overall survival was 91% and 5-year 
cancer-specific survival was 96%. Grade 3 gastrointestinal 
toxicity was observed in 4 patients and 3 patients showed 
grade 3 genitourinary toxicities. No grade 4 gastrointestinal 
or genitourinary side effects were reported. 
 
Conclusion: Gleason score and pre-RT PSA were important 
predictors for bRFS. The dose in salvage radiotherapy should 
be increased to 72 Gy to prevent an early recurrence after 
sRT in patients with a macroscopic recurrence. A higher total 
dose of up to 72 Gy was well tolerated in this cohort of 
patients. 
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Purpose or Objective: The aim of the study was to assess the 
kinetics of the Prostate-Specific Antigen (PSA) in prostate 
cancer patients after stereotactic body radiotherapy using 
CyberKnife System.  
 
Material and Methods: 44 localized prostate adenocarcinoma 
patients (33 low and 11 intermediate risk) without hormonal 
therapy, were irradiated using the CyberKnife Radiosurgical 
System. The prescription dose was 36,25 Gy in five fractions. 
During the 1-year follow-up all the patients had at least six 
PSA measurements – before the treatment (1-2 months before 
RT), during RT (after the 4th fraction) and 1, 3, 6, 12 months 
after RT.  
 
Results: The mean initial PSA value among the patients was 
6,25 ng/ml (range from 3,02 to 17,46 ng/ml). During the 
treatment we observe the PSA increase – the mean value was 
11,89 ng/ml (4,13-30,68ng/ml, 155% of the initial PSA in 
average). In every case we noticed the PSA nadir 12 months 
after the treatment with a mean value of 1,50 ng/ml (0,10- 
4,56 ng/ml). The mean slope of the PSA was 0,56 
ng/ml/month (median 0,46 ng/ml/month). No biochemical 
failure was observed. 
 
Conclusion: The PSA kinetics after treatment can reflect the 
biological effect of radiation on prostate cancer and 
potentially correlate with a clinical outcome. Especially the 
lower value of PSA nadir (<0,5 ng/ml) is considered to 
associate with an increased freedom from biochemical 
failure. The interpretation of PSA slope is more controversial 
however some studies indicates a correlation with clinical 
outcome. Our results are similar to other SBRT studies and 
significantly better than in conventionally-fractionated 
technics. The rapid decline in PSA is particularly worth to be 
underlined. The further follow-up will probably confirm the 
expected good clinical outcome. 
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Purpose or Objective: To describe and compare acute 
toxicity rate in three different radiotherapy (RT) protocols 
for prostate cancer (PC): hypofractionated radiotherapy 
intensity modulated and image-guided radiation therapy 
(Hypo-IMRT-IGRT) group A: 21 fractions/3Gy and group B: 28 
fractions/2.5Gy) and three-dimensional conformal 
radiotherapy standard fractionation (3DCRT) group C: 39 
fractions/2Gy. 
 
Material and Methods: Patients with the diagnosis of PC 
treated with RT between January 1st 2011 to June 30th 2015 
were included. Hypo-IMRT-IGRT were performed using 
internal marker and ExacTrac-X-Ray-system. In 3DCRT group 
not employed internal marker. Acute genitourinary (AGUT) 
and acute gastrointestinal toxicity (AGIT) were assessed 
according to RTOG-EORTC criteria. A p value<0.05 was 
considered significant. Results were expressed as median 
(IQR). Categorical and continuous variables were compared 
with X2 and kruskal-Wallis ran sum test respectively. All 
statistical analysis was performed using R package. The 
institutional review board approved this study. 
 
Results: 242 consecutive patients were retrospectively 
analyzed (group A: 39, group B: 128 and group C: 74). No 
baseline characteristic differences were found (age, PSA, 
TNM, PTV total, bladder and rectal volume). Maximal bladder 
doses and V60 rectal were different within the three groups 
(p=<0.01). AGUT (n): in group A was grade 0: 18; grade 1: 9, 
grade 2: 12; group B grade 0: 35; grade 1: 86; grade 2: 7; and 
group C grade 0: 23; grade 1: 38; grade 2: 13 (p=<0.01). AGIT 
was in group A grade 0: 38; grade 1: 1; grade 2: 0; group B 
grade 0: 121; grade 1: 7; grade 2: 0; and group C grade 0: 65; 
grade 1: 6; grade 2: 3 (p=0.07) Table 1. Comparative AGUT 
between A+B vs. C did not differ. AGIT in A+B group was less 
frequent than C group (p=0.017). AGUT from group A was 
different from group B (p=<0.01). AGIT from A group was not 
different from B group (p=0.75).There were no events > 
grade 3 reported in any group. 
GRADE n( %) 0 1 2 p 
AGUT     <0.01 
Group A  18(46) 9(23) 12(31)  
Group B 35(27) 86(67) 7(5)  
Group C 23(31) 38(51) 38(51)  
AGIT    0.07 
Group A 38(97) 1(3) 0(0)  
Group B 121(95) 7(5) 0(0)  
Group C  65(88) 6(8) 3(4)  
 
Conclusion: Hypo-IMRT-IGRT was associated to lower AGIT 
rate than 3DCRT. Hypo-IMRT-IGRT 21 fractions/3Gy was 
inferior to Hypo-IMRT-IGRT 28 fractions in terms of AGUT. 
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